

pGluA β increases accumulation of A β in vivo and exacerbates its toxicity

Article (Published Version)

Sofola-Adesakin, Oyinkan, Khericha, Mobina, Snoeren, Inge, Tsuda, Leo and Partridge, Lina (2016) pGluA β increases accumulation of A β in vivo and exacerbates its toxicity. *Acta Neuropathologica Communications*, 4 (109). ISSN 2051-5960

This version is available from Sussex Research Online: <http://sro.sussex.ac.uk/id/eprint/70849/>

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:

Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

RESEARCH

Open Access



pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity

Oyinkan Sofola-Adesakin¹, Mobina Khericha^{1,2}, Inge Snoeren^{1,2}, Leo Tsuda³ and Linda Partridge^{1,2*}

Abstract

Several species of β -amyloid peptides (A β) exist as a result of differential cleavage from amyloid precursor protein (APP) to yield various C-terminal A β peptides. Several N-terminal modified A β peptides have also been identified in Alzheimer's disease (AD) brains, the most common of which is pyroglutamate-modified A β (A β _{pE3-42}). A β _{pE3-42} peptide has an increased propensity to aggregate, appears to accumulate in the brain before the appearance of clinical symptoms of AD, and precedes A β ₁₋₄₂ deposition. Moreover, in vitro studies have shown that A β _{pE3-42} can act as a seed for full length A β ₁₋₄₂. In this study, we characterized the *Drosophila* model of A β _{pE3-42} toxicity by expressing the peptide in specific sets of neurons using the GAL4-UAS system, and measuring different phenotypic outcomes. We found that A β _{pE3-42} peptide had an increased propensity to aggregate. Expression of A β _{pE3-42} in the neurons of adult flies led to behavioural dysfunction and shortened lifespan. Expression of A β _{pE3-42} constitutively in the eyes led to disorganised ommatidia, and activation of the c-Jun N-terminal kinase (JNK) signaling pathway. The eye disruption was almost completely rescued by co-expressing a candidate A β degrading enzyme, neprilysin2. Furthermore, we found that neprilysin2 was capable of degrading A β _{pE3-42}. Also, we tested the seeding hypothesis for A β _{pE3-42} in vivo, and measured its effect on A β ₁₋₄₂ levels. We found that A β ₁₋₄₂ levels were significantly increased when A β ₁₋₄₂ and A β _{pE3-42} peptides were co-expressed. Furthermore, we found that A β _{pE3-42} enhanced A β ₁₋₄₂ toxicity in vivo. Our findings implicate A β _{pE3-42} as an important source of toxicity in AD, and suggest that its specific degradation could be therapeutic.

Keywords: Neurodegeneration, Alzheimer's disease, pyroglutamate Abeta, *Drosophila*

Introduction

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by amyloid beta (A β) deposits and neurofibrillary hyperphosphorylated tau tangles [1]. The amyloid cascade, which has undergone some revision in recent years, is the leading hypothesis for the pathology associated with AD, and states that amyloidogenic A β is the trigger of the pathogenic process leading to neuronal cell death [2, 3]. A β induces several stressors, which could lead to neuronal cell death [4]. The c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signaling pathway which influences cell death is activated in response to many forms of stress, such as oxidative stress and endoplasmic reticulum (ER) stress [5, 6]. In particular, A β is able to activate the JNK/SAPK

pathway, and increased phosphorylation of JNK/SAPK has been observed in post-mortem AD brain tissue in comparison to control cases [5, 7].

A β peptides form as a cleavage product from the amyloid precursor protein (APP) [8]. Several species of A β peptides exist, as a result of differential cleavage from APP to yield various C-terminal A β peptides. A β ₄₀ and A β ₄₂ are the most abundant, with A β ₄₂ being the more toxic form [9]. More recently, A β ₄₃ has also been identified as a pathogenic species [10, 11]. There are also several N-terminal truncated/modified A β peptides that have been identified in AD brains, the most common of which is pyroglutamate-modified A β [12–14].

Pyroglutamic (pGlu) acid is generated from N-terminal glutamine during pro-hormone maturation in the secretory pathway; the enzyme glutaminyl cyclase (QC) is directed to the secretory pathway and catalyses the conversion from N-terminal glutamic to pGlu acid [15, 16]. Interestingly, A β undergoes this post-translational modification at its amino terminus, also catalyzed by QC [17], which is up-

* Correspondence: l.partridge@ucl.ac.uk

¹Institute of Healthy Ageing, and G.E.E., University College London, Darwin Building, Gower Street, London WC1E 6BT, UK

²Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Straße 9B, 50931 Cologne, Germany

Full list of author information is available at the end of the article



regulated in the cortex of patients with AD [18]. Of particular interest is the highly abundant $A\beta_{pE3-42}$, which is generated by cleavage of the first 2 amino acids of the $A\beta$ peptide, followed by pGlu-modification of glutamate in the third amino acid position, which is thought to stabilize it and/or promote its aggregation propensity [14].

Interestingly, water soluble $A\beta$, which appear before plaques is made up predominantly of $A\beta_{pE3-42}$ [19], and indeed $A\beta_{pE3-42}$ accumulate early on in the brain before the appearance of clinical symptoms and $A\beta_{1-42}$ deposition [20–23]. Moreover, in vitro studies have shown that $A\beta_{pE3-42}$ has an increased propensity to aggregate in comparison to $A\beta_{1-42}$ and can act as a seed/primer for full length $A\beta_{1-42}$ [14, 24, 25]. $A\beta_{pE3-42}$ behaves in a prion-like manner, whereby only small quantities of $A\beta_{pE3-42}$ are able to increase the amount of metastable low-n $A\beta_{1-42}$ oligomers in vitro [25]. These attributes have created a lot of interest in $A\beta_{pE3-42}$ peptides, and several groups have suggested that they are important in initiating the pathological cascade of AD [14, 20].

Interestingly, $A\beta_{pE3-42}$ plaque load has been observed in brain autopsies of familial, sporadic cases and controls although, importantly, oligomeric $A\beta_{pE3-42}$ was only found in the familial and sporadic cases [26]. There is also a likely role for $A\beta_{pE3-42}$ in intra-neuronal AD toxicity. A study that expressed $A\beta_{Q3-42}$ under the Thy-1 promoter in mice (glutamine was used instead of glutamate because it is a better substrate for pyroglutamate conversion, [15]) showed increased levels of intra-neuronal $A\beta_{pE3-42}$, severe neurological impairment and loss of Purkinje cells [27]. Furthermore, $A\beta_{pE3-42}$ expressing mice which display neuronal loss [28], when crossed into a tau KO background were almost completely protected against neuronal loss, establishing a functional connection between pGlu $A\beta$ and tau [25]. Moreover, transgenic mouse models of AD that develop more severe pathology, as measured by the appearance of early neurological phenotypes and amyloid plaque deposition, tend to have high levels of $A\beta_{pE3-42}$ [14].

Over-expression or reduction of QC has also been shown to exacerbate or rescue behavioural phenotypes and plaque pathology in an AD mouse model [29]. Interestingly, QC KO mice showed a reduction in both $A\beta_{pE3-42}$ and $A\beta_{1-42}$ levels, again supporting the idea that $A\beta_{pE3-42}$ plays a role in seeding $A\beta_{1-42}$ [29]. The data also demonstrate the importance of QC, and suggest that a reduction of QC might be a promising therapeutic strategy.

Many signaling pathways/molecules are conserved between flies and humans, and QC is 1 of them. *Drosophila* has 2 QCs – Drome QC and isoDrome QC, which have different subcellular locations [30]. IsoDrome QC more closely resembles the mammalian homologue [30]. Interestingly, treatment of $A\beta_{Q3-42}$ transgenic flies with a QC inhibitor led to reduced $A\beta_{pE3-42}$ levels [18], highlighting

the usefulness of *Drosophila* to investigate the molecular pathogenicity of $A\beta_{pE3-42}$. Several labs have generated fly models that express various $A\beta$ peptides [31–33]. $A\beta_{Q3-42}$ fly models are available, but have not been fully characterized or utilized to test the “seeding hypothesis”.

In this study, we characterized a *Drosophila* model of $A\beta_{pE3-42}$ toxicity in the fruit-fly. Expression specifically in adult fly neurons led to behavioural dysfunction and shortened lifespan. Expression of the $A\beta_{pE3-42}$ constitutively in the eyes led to disorganised ommatidia, which was ameliorated by neprilysin2. Furthermore, we show for the first time that neprilysin2 was able to degrade pyroglutamate $A\beta$.

Several recent studies have suggested that $A\beta_{pE3-42}$ can act as a seed for $A\beta_{1-42}$, and such a role has been demonstrated in vitro. $A\beta_{pE3-42}$ has been shown to increase the amount of metastable low-n $A\beta_{1-42}$ oligomers in vitro [25]. Furthermore, peri-hippocampal injection of $A\beta_{pE3-42}$ into APPswe/NOS2-/- AD mice led to the presence of both $A\beta_{pE3-42}$ and conventional $A\beta$ plaques, which the authors mention was hardly seen in sham injected AD mice or WT mice injected with $A\beta_{pE3-42}$ [25]. However, the direct effect of $A\beta_{pE3-42}$ on $A\beta_{1-42}$ in vivo remains to be assessed, because the genetic background of the AD mouse lines are mutant for several genes that may well be affected by $A\beta_{pE3-42}$. Furthermore, to control for the specificity of the $A\beta_{pE3-42}$ species in causing enhanced plaque formation, an important control of peri-hippocampal injection of $A\beta_{1-42}$ into the AD mice is missing from their studies.

We have utilized the *Drosophila* model to our advantage by expressing multiple transgenes at the same time to test this seeding hypothesis in vivo, and thus determine whether $A\beta_{pE3-42}$ could be a target for therapeutic intervention, and/or a diagnostic marker. We found that total $A\beta_{1-42}$ levels and toxicity are greatly increased when $A\beta_{pE3-42}$ is co-expressed. These data suggest that $A\beta_{pE3-42}$ is able to stabilise $A\beta_{1-42}$ in vivo.

Materials and methods

Fly stocks and maintenance

All fly stocks were maintained either at 25 °C or 28 °C on a 12:12-h light:dark cycle at constant humidity on a standard sugar-yeast (SY) medium (15g l⁻¹ agar, 50 g l⁻¹ sugar, 100 g l⁻¹ autolysed yeast, 100g l⁻¹ nipagin and 3 ml l⁻¹ propionic acid). Adult-onset, neuronal-specific expression of $A\beta$ peptide was achieved by using the elav GeneSwitch (elavGS)-UAS system. ElavGS was derived from the original elavGS 301.2 line [34] and obtained as a generous gift from Dr H. Tricoire (CNRS, France), GMR driver was from Bloomington stock centre. UAS- $A\beta_{1-42}$ line was obtained from Dr D. Crowther [35]. UAS- $A\beta_{Q3-42}$ line has been previously described [36], briefly the rat pre pro-enkephalin signaling sequence was cloned upstream

A β _{Q3-42} and put into the EcoR1 site of the pUAST vector, the construct then gets processed via prohormone convertases and glutaminyl cyclase to generate A β _{pE3-42} [17, 37] (Additional file 1: Figure S1). GMR, elavGS and UAS-lines used in all experiments were backcrossed six times into the *w*¹¹¹⁸ genetic background. Expression by elavGS was induced by treatment with mifepristone (RU486; 200 μ M) added to the standard SY medium. In the absence of mifepristone (RU486; -RU), the transgene remains transcriptionally silent. Following treatment with RU486, A β _{Q3-42} peptide is expressed.

Lifespan analyses

For all experiments, flies were raised at a standard density on standard SY medium in 200 mL bottles. Two days after eclosion once-mated females were transferred to experimental vials containing SY medium with or without RU486 (200 μ M) at a density of 10 flies per vial (120 flies per genotype were used in Fig. 2, and 150 flies per genotype were used in Fig. 4). Deaths were scored almost every other day and flies were transferred to fresh food. Data are presented as survival curves and statistical analysis was performed using log-rank tests to compare survival of groups.

Negative geotaxis assays

Climbing assays were performed at 25 °C according to previously published methods [31]. Climbing was analysed every 2–3 days post-RU486 treatment. Fifteen adult flies were placed in a vertical column, then their rate of climb to the top of the column was analysed. Flies reaching the top (12 cm) and flies remaining at the bottom of the column after a 30 s period were counted separately, and 3 trials were performed for each experiment. Scores recorded were the mean number of flies at the top (n_{top}), the mean number of flies at the bottom (n_{bottom}) and the total number of flies assessed (n_{tot}). A performance index (PI) defined as $\frac{1}{2}(n_{tot} + n_{top} - n_{bottom})/n_{tot}$ was calculated. Data are presented as the mean $PI \pm SEM$ obtained in 3 independent experiments for each group, and analyses of variances (ANOVA) were performed using JMP software.

Quantification of A β peptide by ELISA

Quantification of A β was carried out as previously described [38]. To extract total A β , 5 *Drosophila* heads were homogenised in 50 μ L GnHCl extraction buffer (5 M Guanidine HCl, 50 mM Hepes pH 7.3, protease inhibitor cocktail (Sigma, P8340) and 5 mM EDTA), centrifuged at 21,000 g for 5 min at 4 °C, and cleared supernatant retained as the total fly A β sample. Alternatively, for soluble and insoluble pools of A β , 25 fly heads were homogenised in 50 μ L tissue homogenisation buffer (250 mM sucrose, 20 mM Tris base, 1 mM EDTA,

1 mM EGTA, protease inhibitor cocktail (Sigma) then mixed further with 50 μ L diethyl acetate (DEA) buffer (0.4 % DEA, 100 mM NaCl and protease inhibitor cocktail). Samples were centrifuged at 135,000 g for one hour at 4 °C (Beckman OptimaTM Max centrifuge, TLA120.1 rotor), and supernatant retained as the cytosolic, soluble A β fraction. Pellets were resuspended in 200 μ L ice-cold formic acid (FA; 70 %), and sonicated. Samples were re-centrifuged at 135,000 g for one hour at 4 °C, then 100 μ L of supernatant diluted with 1 mL FA neutralisation buffer (1 M Tris base, 0.5 M Na₂HPO₄, 0.05 % NaN₃) and retained as the insoluble, formic acid-extractable A β fraction. A β content was measured using the hAmyloid β 42 ELISA kits, X-42 and N3pE-42 (IBL INTERNATIONAL). N of 3 or 4 individual samples were diluted in sample/standard dilution buffer and ELISA performed according to the manufacturers' instructions. Protein extracts were quantified using the Bradford protein assay (Bio-Rad protein assay reagent; Bio-Rad laboratories (UK) Ltd) and the amount of A β in each sample expressed as a ratio of the total protein content (pmol/g total protein).

Western blotting

For total A β extraction, we used a procedure previously described [11]. 20 heads per biological replicate were homogenized in 100 μ L of 70 % formic acid. Samples were centrifuged at 16,000 g for 20 min at room temperature. The supernatant was collected and evaporated using a SpeedVac. The pellet was resuspended in 100 μ L 2 \times LDS containing reducing agent (Invitrogen) and homogenized by sonication (10 pulses). Samples were then boiled at 100 °C for 10 min and 15 μ L of each sample were used for western blotting to determine total A β levels. For LDS/SDS oligomer A β extraction, 20 heads per biological replicate were homogenized in 100 μ L 2 \times LDS containing reducing agent (Invitrogen). Samples were incubated on ice for 30 min and then boiled at 100 °C for 10 min. 15 μ L per sample were used for western blotting to evaluate LDS/SDS-stable A β oligomers. Proteins were separated on 16.5 % Tris-Tricine Criterion gels (Biorad) blotted onto nitrocellulose membranes. Membranes were incubated in a blocking solution containing 5 % milk proteins in TBST for 1 h at room temperature, then probed with primary antibody diluted in TBST + 5 % BSA overnight at 4 °C. 82E1 A β 1-42 Antibody was from Takara, used at 1 in 100 dilution.

For pJNK western blot analyses, total protein was extracted from 5 fly heads in 30 μ L 2 \times LDS buffer containing reducing agent (Invitrogen). Membranes were incubated in a blocking solution containing 5 % BSA in TBST for 1 h at room temperature, then probed with primary antibody diluted in TBST + 5 % BSA overnight at 4 °C. mouse monoclonal phospho-SAPK/JNK (T183/

Y185) antibody was from cell signaling, used at 1 in 1000 dilution. Rabbit polyclonal actin antibody was from abcam and used at 1 in 1000 dilution.

Quantitative RT-PCR

Total RNA was extracted from 20 to 25 fly heads using TRIzol (GIBCO) according to the manufacturers' instructions. The concentration of total RNA purified for each sample was measured using an *Eppendorf biophotometer*. 1 µg of total RNA was then subjected to DNA digestion using DNase I (Ambion), immediately followed by reverse transcription using the Superscript II system (Invitrogen) with oligo(dT) primers. Quantitative PCR was performed using the PRISM 7000 sequence-detection system (Applied Biosystems), SYBR Green (Molecular Probes), ROX Reference Dye (Invitrogen), and Hot StarTaq (Qiagen, Valencia, CA) by following manufacturers' instructions. Each sample was analysed at a minimum in triplicate with both target gene ($A\beta_{Q3-42}$ or NEP2) and control gene (RP49) primers in parallel. The primers for the $A\beta$ transgenes were directed to the 5' end and 3' end of the $A\beta$ coding sequence: forward CGACATGACTCAGGTTATGAAGTT; reverse GACAACGCCCACCAT Nephrin-2 primers are, forward ACGAGGTCAACTGGATGGAC and reverse GTCGAGCTTGGCGTAGTAGG. RP49 primers were as follows: forward ATGACCATCCGCCCAGCATCAGG; reverse ATCTCGCCGCAGTAAACG.

Eye phenotype

Eye images of 2/3-day-old female flies expressing $A\beta_{PE3-42}$ under the control of the GMR-Gal4 driver at 28 °C were taken. Nail polish imprint of the external eye was carried out as previously described. For adult eye transverse sections, adult heads were fixed, dehydrated, sectioned (10 microns thick) and stained with Harry's hematoxylin. To investigate the eye phenotype of double transgenic $A\beta_{1-42}$; $A\beta_{Q3-42}$ flies, we kept the flies at 25 °C to minimize $A\beta_{PE3-42}$ eye phenotype. Images were taken with ZEISS Axioskop2 plus microscope. The eye phenotype was quantified by assigning numbers, from zero to 2 to individual flies chosen at random. Normal looking eyes were given zero, flies with moderate eye phenotype were assigned 1, and flies with strong eye phenotype were given 2, ($N = 5 - 6$ flies per genotype). The scoring was carried out blind by 2 independent researchers.

Statistical analyses

For lifespan analyses, log-rank tests were used to assess for statistical differences. Eye phenotype was presented as means \pm SEM, and statistically assessed by Student's *t* test. Other data are presented as means \pm SEM obtained in at least 3 independent experiments, and differences between means were assessed by either Student's *t* test

or 2-way analysis of variance (ANOVA) using JMP (version 12.0) software (SAS Institute, Cary, NC, USA).

Results

Pyroglutamate $A\beta$ ($A\beta_{PE3-42}$) expression can be induced in the adult *Drosophila* nervous system


A fly model that expresses $A\beta_{E3-42}$ has been described [39], however, we are utilising a previously generated $A\beta_{Q3-42}$ transgenic fly model for this study, since glutamine is a better substrate for pyroglutamate conversion than glutamate [14]. $A\beta_{Q3-42}$ fly models have been generated but little characterized [18, 36]. To ensure that these flies could express $A\beta_{Q3-42}$, we drove expression of the $A\beta_{Q3-42}$ transgene in adult neurons with the inducible pan-neuronal driver, elav GeneSwitch (elavGS) [31, 34]. We measured RNA levels of $A\beta_{Q3-42}$ flies in adult neurons, after treating elavGS;UAS- $A\beta_{Q3-42}$ flies with the activator mifepristone (RU486) for 7 days, starting at 2 days post-eclosion (Fig. 1a). We found a significant increase in $A\beta_{Q3-42}$ transcripts in RU486-treated elavGS;UAS- $A\beta_{Q3-42}$ flies in comparison to untreated flies (Fig. 1a). Furthermore, we confirmed that the flies generate pyroglutamate-modified $A\beta$ by measuring $A\beta_{PE3-42}$ protein levels specifically. $A\beta_{PE3-42}$ protein levels in adult neurons of elavGS;UAS- $A\beta_{Q3-42}$ flies treated with RU486 for 21 days, starting at 2 days post-eclosion were significantly increased in comparison to untreated flies (Fig. 1b). These data demonstrate that $A\beta_{PE3-42}$ can be successfully generated in the flies.

Expression of $A\beta_{PE3-42}$ causes shortened lifespan, neuronal dysfunction, disorganised eye phenotype, and activates JNK in *Drosophila*

To determine whether expression of $A\beta_{PE3-42}$ in neurons is toxic, we used the elavGS driver to express $A\beta_{PE3-42}$ peptide in adult neurons, and measured the effects on behaviour. Impaired geotaxis is a behavioural measure of neuronal dysfunction and can be assessed using a climbing assay [31]. elavGS;UAS- $A\beta_{Q3-42}$ flies were treated with RU486 starting at 2 days post-eclosion, and their climbing ability was subsequently recorded. Flies expressing $A\beta_{PE3-42}$ displayed substantially increased rate of decline in negative geotaxis with age in comparison to the -RU or driver (elavGS) alone control flies (Fig 2a and Additional file 2: Figure S2).

We also measured the effects of $A\beta_{PE3-42}$ on lifespan in comparison to the -RU control flies, by treating elavGS;UAS- $A\beta_{Q3-42}$ flies with RU486 starting at 2 days post-eclosion and recording their subsequent survival. Expression of $A\beta_{PE3-42}$ in adult neurons significantly shortened median (54 %) and maximum lifespan (31 %) in comparison to control elavGS;UAS- $A\beta_{Q3-42}$ -RU flies (Fig. 2b).

To assess the effects of $A\beta_{PE3-42}$ on neurodegeneration, we expressed $A\beta_{PE3-42}$ constitutively in the fly eye



using the GMR-GAL4 driver and observed the effect on the organization of the ommatidia, an assay that has been used extensively to characterise fly models of neurodegenerative diseases [35]. Expression of Aβ_{pE3-42} caused disorganisation of the ommatidia in these flies, presenting with eye roughness and fused ommatidia in comparison to flies expressing EGFP, and w1118 control flies (Fig. 2c).

The JNK/SAPK signaling pathway which influences cell death is activated by Aβ, and has been suggested to contribute to Aβ mediated cell death in fly models expressing Aβ₁₋₄₂ [40, 41]. To determine whether Aβ_{pE3-42} expressing flies are also capable of activating JNK, we measured the levels of phosphorylated JNK as a read-out

in the flies, by western blot analyses. We found a significant increase in the level of phosphorylated JNK in flies expressing Aβ_{pE3-42} (GMR-GAL4/+; Aβ_{Q3-42}/+) in comparison to control flies expressing LACZ (GMR-GAL4/LACZ), 6 days post-eclosion (Fig. 2d).

Co-expression of neprilysin2 suppresses the toxicity of Aβ_{pE3-42} expressing flies

Neprilysin (NEP) and its close homologue Neprilysin2 (Nep2) are candidate Aβ degrading enzymes, and regulate amyloid protein levels in AD [42–44]. We next determined whether the fly orthologue, *nep2*, which has been shown previously to significantly reduce Aβ₁₋₄₂ levels and toxicity, is able to similarly ameliorate Aβ_{pE3-42} induced toxicity. We made use of the rough eye/disorganised ommatidia phenotype, and found that co-expression of NEP2 using the EP(3)3549 *Drosophila* strain, with the GMR-GAL4 driver almost completely suppressed both the external disorganised ommatidia and internal retinal degeneration of the Aβ_{pE3-42} expressing flies (Fig. 3a). We confirmed that the EP(3)3549 strain had a significant expression of NEP2 levels by RTPCR (Additional file 3: Figure S3A).

Co-expression of neprilysin2 reduces Aβ_{pE3-42} protein levels

To understand the mechanism by which NEP2 ameliorates the Aβ_{pE3-42} eye phenotype, we measured total Aβ load, and Aβ_{pE3-42} protein levels specifically in the flies, 7 days post-eclosion. Interestingly, we found by ELISA analyses that Aβ load and importantly, Aβ_{pE3-42} levels were significantly reduced in flies co-expressing Aβ_{pE3-42} and NEP2 in comparison to flies co-expressing Aβ_{pE3-42} and EGFP as a control (Additional file 3: Figure S3B and Fig. 3b). Furthermore, the reduction we see at the protein level is not due to reduced RNA levels, since this reduction was not observed in the RNA by RTPCR analyses, 7 days post eclosion (Additional file 3: Figure S3C). These data demonstrate a major role of NEP2 in ameliorating Aβ_{pE3-42} induced toxicity, by reducing Aβ_{pE3-42} protein levels.

Aβ_{pE3-42} is more toxic than Aβ₁₋₄₂ in *Drosophila*

Data from mouse models have indicated that the appearance of Aβ_{pE3-42} correlates with increased pathogenicity [45]. To determine whether Aβ_{pE3-42} peptide was more toxic in comparison to Aβ₁₋₄₂, we needed 2 lines with comparable levels of Aβ peptide. We expressed the peptides with the elavGS driver line, by treating Aβ_{Q3-42} and Aβ₁₋₄₂ transgenic flies independently with RU486 starting at 2 days post-eclosion, for 2 days and 21 days, and measured Aβ protein levels in adult neurons, taking advantage of an ELISA kit that recognizes an epitope in the middle of both Aβ_{pE3-42} and Aβ₁₋₄₂ peptides. We





Fig. 2 Expression of Aβ_{PE3-42} causes locomotor dysfunction, shortened lifespan, eye disruption, and JNK activation in *Drosophila*. **a** Climbing ability of *elavGS/UAS-AβQ3-42* flies on + and - RU486 SY medium were assessed at the indicated time-points. Data are presented as the average performance index (PI) ± SEM and were compared using 2-way ANOVA (number of independent tests (n) = 3 *P < 0.001. **b**) Expression of Aβ_{PE3-42} in adult neurons shortens lifespan. Survival curves are depicted and data were compared using the log-rank test, *P < 0.001 comparing *elavGS/UAS-AβQ3-42* + RU flies to -RU flies. **c** Expression of Aβ_{PE3-42} causes a neurodegenerative eye phenotype. First 2 images from left to right are light microscopy images and latter 2 images are nail varnish imprints of eyes (magnification is 25x, and 40x objectives for close up images). From left to right, GMR-GAL4/UAS-EGFP, GMR-GAL4/+;UAS-AβQ3-42/+, GMR-GAL4/+, GMR-GAL4/+;UAS-AβQ3-42/+. Note compressed and fused ommatidia in AβQ3-42 expressing flies in comparison to control flies (GMR-GAL4/UAS-EGFP or GMR-GAL4/+). Flies were grown at 28 °C. **d** Expression of Aβ_{PE3-42} increases the levels of phosphorylated JNK. Data are presented as means ± SEM and were analysed by Student t test, *P < 0.05 comparing GMR-GAL4/+;UAS-AβQ3-42/+ flies to control GMR-GAL4/UAS-LACZ flies

found similar levels of total Aβ protein in the Aβ_{PE3-42} and Aβ₁₋₄₂ expressing flies (Fig. 4a and b). However, the solubility/aggregation propensity of Aβ differed between the Aβ_{PE3-42} and Aβ₁₋₄₂ expressing flies, with Aβ_{PE3-42} expressing flies having a significantly increased ratio of insoluble to total Aβ in comparison to Aβ₁₋₄₂ expressing

flies (Fig. 4c). Aβ_{PE3-42} expressing flies also suffered increased toxicity, because expression of Aβ_{PE3-42} in adult neurons significantly shortened median (27 %) and maximum (23 %) lifespan in comparison both to control w1118;*elavGS* and Aβ₁₋₄₂ expressing flies (Fig. 4d), demonstrating a more toxic effect of the Aβ_{PE3-42} peptide.



pGluA β increases accumulation of A β in vivo

A β _{pE3-42} has been shown to increase the amount of metastable low-n A β ₁₋₄₂ oligomers in vitro [25]. To study in vivo, the seeding effect of A β _{pE3-42}, we co-expressed A β _{pE3-42} and A β ₁₋₄₂ peptides directly and compared the effects to those seen in flies expressing A β ₁₋₄₂. We expressed A β ₁₋₄₂ or A β _{pE3-42} constitutively with the GMR-GAL4 driver line, and measured at 2–3 days post-eclosion total protein levels of flies expressing either peptide. We found a substantial increase in insoluble A β levels and a

significant decrease in soluble A β detected in A β _{pE3-42} expressing flies in comparison to A β ₁₋₄₂ expressing flies with ELISA (Fig. 5a). There was also a significant increase in total A β levels in A β ₁₋₄₂; A β _{pE3-42} expressing flies in comparison to A β ₁₋₄₂;A β ₁₋₄₂ expressing flies (Fig. 5a and Additional file 4: Figure S4). Furthermore, we found a shift in A β solubility in A β ₁₋₄₂; A β _{pE3-42} expressing flies, with a significant decrease in soluble A β and a substantial increase in insoluble A β in comparison to A β ₁₋₄₂;A β ₁₋₄₂ expressing flies (Fig. 5a).

We next investigated the effect of co-expressing A β ₁₋₄₂; A β _{pE3-42} specifically on A β ₁₋₄₂ stability, and whether this contributed to the increased total A β levels. We measured A β ₁₋₄₂ levels by western blot, by selecting an antibody that detects A β ₁₋₄₂, but not A β _{pE3-42} (Fig. 5b and Additional file 5: Figure S5). Flies co-expressing A β ₁₋₄₂; A β _{pE3-42} had increased levels of A β ₁₋₄₂ levels in comparison to flies expressing a single copy of A β ₁₋₄₂, which do not accumulate enough protein levels for quantification by western blot analyses (Fig. 5a and Additional file 5: Figure S5). However, A β ₁₋₄₂ was specifically detected in flies containing 2 copies of the A β ₁₋₄₂ transgene (A β ₁₋₄₂;A β ₁₋₄₂), confirming protein expression of this line with the antibody (Fig. 5b). Interestingly, the flies co-expressing A β ₁₋₄₂;A β ₁₋₄₂ significantly expressed lower levels of A β ₁₋₄₂ in comparison to flies co-expressing A β ₁₋₄₂; A β _{pE3-42} (Fig. 5b).

pGluA β enhances A β toxicity

Since A β _{pE3-42} increased the stability of A β ₁₋₄₂, we assessed whether it also increased the toxicity of A β ₁₋₄₂, using the rough eye/disorganised ommatidia phenotype. Flies co-expressing A β ₁₋₄₂; A β _{pE3-42}, but not those expressing A β ₁₋₄₂;A β ₁₋₄₂ presented with disorganised ommatidia, 2 days post eclosion, and this phenotype was stronger than in flies expressing A β _{Q3-42} alone (Fig. 5c and Additional file 6: Figure S6) suggesting that A β _{pE3-42} enhances the toxicity of A β ₁₋₄₂.

Collectively, these data suggest that A β _{pE3-42} is able to increase the stability of the A β ₁₋₄₂ peptide and exacerbate its toxicity in vivo.

Discussion

A β _{pE3-42} is increasingly thought to play a pivotal role in the pathogenesis of Alzheimer's disease [14]. Although previous studies in vitro have suggested that A β _{pE3-42} acts as a seed for A β stability, and some correlative work has been done in vivo [25], this seeding behaviour and its consequences have not been examined in vivo. Our study demonstrates that A β _{pE3-42} increases the levels of A β ₁₋₄₂, presumably by increasing its stability, and that it enhances toxicity of the A β ₁₋₄₂ peptide, as observed in flies co-expressing A β _{pE3-42} and A β ₁₋₄₂ in comparison to flies expressing 2 copies of A β ₁₋₄₂.




Fig. 4 Aβ_{pE3-42} is more toxic than Aβ₁₋₄₂ in *Drosophila*. Following treatment with RU486, Aβ₁₋₄₂ and Aβ_{pE3-42} peptides were expressed at similar levels, quantified at 2 days and 21 days post-RU486 treatment (**a**) and (**b**) respectively. **c** A significant increase in the amount of insoluble to total Aβ protein levels in Aβ_{pE3-42} expressing flies in comparison to Aβ₁₋₄₂ expressing flies was observed when quantified at 21 days post-RU486 treatment. Data are presented as means ± SEM and were analysed by Student's *t* test, *P* < 0.01. **d** Expression of Aβ_{pE3-42} specifically in adult neurons shortens lifespan significantly relative to both Aβ₁₋₄₂ and w¹¹¹⁸ control. Survival curves are depicted and data were compared using the log-rank test.

**P* < 0.001 comparing elavGS/UAS-Aβ_{Q3-42} + RU flies to elavGS/+ and UAS-Aβ₁₋₄₂ /+;elavGS/+ +RU flies

First, we characterized the model. Expression of the Aβ_{pE3-42} peptide specifically in adult fly neurons led to behavioural dysfunction and shortened lifespan, and constitutive expression in the eyes led to disorganised ommatidia. Furthermore, we found that Aβ_{pE3-42} was able to activate the JNK signaling pathway, suggesting a role for this cell death activating pathway in Aβ_{pE3-42} mediated toxicity.

Interestingly, we found that we could ameliorate the Aβ_{pE3-42} toxicity by over expressing Neprilysin2. Increasing the expression of several candidate *in vivo* Aβ degrading enzymes, such as NEP or Insulin degrading

enzyme (IDE) have been shown to reduce the cerebral amyloid plaque burden observed in APP over-expressing mice [46]. However, direct interactions between Aβ_{pE3-42} and Neprilysin have not been investigated. We found that over-expression of *Drosophila* NEP2 was able to reduce Aβ_{pE3-42} levels and improve considerably the disorganised ommatidia, demonstrating for the first time that, although Aβ_{pE3-42} may aggregate more than Aβ₁₋₄₂, NEP2 is capable of degrading pyroglutamate-modified Aβ.

Also, we found that these flies had an increase in the ratio of insoluble to total Aβ levels in comparison to flies expressing Aβ₁₋₄₂, confirming the propensity of Aβ_{pE3-42}




Fig. 5 pGluAβ increases accumulation of Aβ in vivo, and exacerbates toxicity **(a)**. Flies expressing Aβ₁₋₄₂ had significantly more soluble Aβ, $P < 0.05$ but less insoluble Aβ, $P < 0.0001$ in comparison to flies expressing Aβ_{pE3-42}. Flies co-expressing Aβ₁₋₄₂ and Aβ_{pE3-42} had significantly more insoluble Aβ, $P < 0.01$ but less soluble Aβ $P < 0.05$ Aβ in comparison to flies co-expressing Aβ₁₋₄₂ and Aβ₁₋₄₂. Data are presented as means ± SEM and were analysed by Student's *t*-test. **(b)** There was a significant increase in Aβ₁₋₄₂ accumulation in flies co-expressing Aβ₁₋₄₂;Aβ_{pE3-42} in comparison to flies expressing either a single copy of Aβ₁₋₄₂ (expressing one single copy of Aβ₁₋₄₂ does not accumulate enough protein levels for quantification by western blot analyses), or flies expressing 2 copies of Aβ₁₋₄₂, $P < 0.05$. Data are presented as means ± SEM and were analysed by Student's *t* test. GMR-GAL4/+;UAS-Aβ₁₋₄₂/+, GMR-GAL4/+;UAS-Aβ_{Q3-42}/+, GMR-GAL4/UAS-Aβ₁₋₄₂;UAS-Aβ₁₋₄₂/+ and GMR-GAL4/+;UAS-Aβ₁₋₄₂/UAS-Aβ_{Q3-42} flies were used for **(a)** and **(b)**. **(c)** Co-expression of Aβ₁₋₄₂ and Aβ_{pE3-42} led to a disorganized eye phenotype that was absent in flies co-expressing Aβ₁₋₄₂ and Aβ₁₋₄₂, and worse than in Aβ_{pE3-42} expressing flies. From left to right, GMR-GAL4/+;UAS-Aβ_{Q3-42}/+, GMR-GAL4/UAS-Aβ₁₋₄₂;UAS-Aβ₁₋₄₂/+ and GMR-GAL4/+;UAS-Aβ₁₋₄₂/UAS-Aβ_{Q3-42} flies. Flies were grown at 25 °C

to aggregate as previously described [14]. Furthermore, we found that Aβ_{pE3-42} was more toxic than Aβ₁₋₄₂ peptide.

Another interesting finding from our analyses is the increase in Aβ levels observed in response to Aβ_{pE3-42}. We found a general increase in total Aβ levels in flies co-expressing Aβ_{pE3-42} and Aβ₁₋₄₂, and there was also an increase in the ratio of insoluble Aβ to total Aβ levels in these flies. To determine what role Aβ₁₋₄₂ might have in this, we measured Aβ₁₋₄₂ levels specifically by western

blot analyses. Interestingly, we found that total Aβ₁₋₄₂ levels were increased when Aβ_{pE3-42} was co-expressed. Nussbaum et al. showed that Aβ peptides oligomerise by different pathways, and that the low-*n* oligomers of Aβ_{pE3-42} are structurally distinct from Aβ₁₋₄₂, and far more cytotoxic, in the order of Aβ_{pE3-42} /Aβ₁₋₄₂ > Aβ_{pE3-42} > Aβ₁₋₄₂ [25]. We found that co-expressing 1 copy each of Aβ₁₋₄₂ and Aβ_{pE3-42} increased the accumulation of Aβ₁₋₄₂, and was more toxic than expressing 2 copies of Aβ₁₋₄₂,

indicating that $A\beta_{pE3-42}$ is able to stabilise $A\beta_{1-42}$ in a different manner to over expressing the $A\beta_{1-42}$ peptide, perhaps by affecting its structure.

Conclusions

We have tested and validated the $A\beta_{pE3-42}$ seeding hypothesis and shown that indeed $A\beta_{pE3-42}$ increases the levels of $A\beta$, and that $A\beta_{pE3-42}$ enhances pathology in this AD model. These results raise $A\beta_{pE3-42}$ as both a potential biomarker and new therapeutic target in AD. Furthermore, because *Drosophila* does not inherently express $A\beta$, the observation that expression of $A\beta_{pE3-42}$ is able to cause toxicity independent of its effect on $A\beta_{1-42}$ suggests that it is capable of initiating toxicity in other ways. It would be interesting to uncover downstream pathways that are modulated specifically by $A\beta_{pE3-42}$, and the fly provides a powerful context for pursuing this question with genetic screens.

Additional files

Additional file 1: Figure S1. Generation of $A\beta_{pE3-42}$. The proenkephalin signaling peptide upstream of $A\beta_{Q3-42}$ is cleaved by prohormone convertases, $A\beta_{Q3-42}$ is then released, and glutaminy cyclase catalyses its conversion to $A\beta_{pE3-42}$. (PDF 271 kb)

Additional file 2: Figure S2. Expression of $A\beta_{pE3-42}$ causes locomotor dysfunction. Climbing ability of elavGS/UAS- $A\beta_{Q3-42}$ and elavGS flies on + RU486 SY medium was assessed at the indicated time-points (see Materials & Methods). Expression of $A\beta_{pE3-42}$ in adult neurons reduced climbing ability of the flies in comparison to control elavGS driver flies. Data are presented as the average performance index (PI) \pm SEM and were compared using 2-way ANOVA (number of independent tests (n) = 3 P < 0.01). (PDF 306 kb)

Additional file 3: Figure S3. (A). Confirming the expression of Neprilysin 2 in the EP(3)3549 fly strain. There was a significant increase in *nep2* transcript levels in the flies expressing the EP(3)3549 EP element, in comparison to the control fly lines expressing LACZ. Data are presented as means \pm SEM and were analysed by student's *t*-test, P < 0.001. (B) Neprilysin2 significantly reduces $A\beta$ protein levels, $*P$ < 0.001, $A\beta_{X-42}$ levels were quantified by ELISA. Data are presented as means \pm SEM and were analysed by Student *t* test. (C) Neprilysin2 does not reduce $A\beta_{Q3-42}$ RNA levels. There was a significant increase in $A\beta_{Q3-42}$ RNA levels in flies co-expressing $A\beta_{Q3-42}$ and NEP2 in comparison to flies expressing $A\beta_{Q3-42}$ and EGFP, by quantitative RTPCR, P < 0.01, student's *t*-test. GMR-GAL4 was used to drive expression of $A\beta_{Q3-42}$ transgenic flies. (PDF 369 kb)

Additional file 4: Figure S4. pGluA β increases accumulation of $A\beta$ in vivo. Flies co-expressing $A\beta_{1-42}$ and $A\beta_{pE3-42}$ peptide, had significantly higher $A\beta$ levels than flies co-expressing $A\beta_{1-42}$ and $A\beta_{1-42}$. Data are presented as means \pm SEM and were analysed by student's *t*-test, P < 0.01. GMR-GAL4 was used to drive expression of $A\beta_{1-42}$ and $A\beta_{Q3-42}$ transgenic flies. (PDF 417 kb)

Additional file 5: Figure S5. pGluA β increases accumulation of $A\beta_{1-42}$ in vivo. (A). Flies co-expressing $A\beta_{1-42}$ and $A\beta_{pE3-42}$ peptide, had substantially more $A\beta_{1-42}$ levels than flies expressing $A\beta_{1-42}$ alone. $A\beta$ was not detected in flies expressing a single copy of $A\beta_{1-42}$ because it does not accumulate enough protein. However, $A\beta_{1-42}$ was detected in flies expressing 2 copies of $A\beta_{1-42}$ (B), confirming protein expression in these flies with the antibody. Furthermore, to validate specificity, $A\beta_{1-42}$ was not detected in flies expressing either a single copy or double copy of $A\beta_{pE3-42}$. GMR-GAL4 was used to drive expression of $A\beta_{1-42}$ and $A\beta_{Q3-42}$ transgenic flies. (PDF 10727 kb)

Additional file 6: Figure S6. Blind scoring of disorganised eye phenotype. The data demonstrate a significant difference in the degree of severity of eye roughness in flies co-expressing $A\beta_{1-42}$ and $A\beta_{pE3-42}$ in comparison to flies

expressing either 2 copies of $A\beta_{1-42}$ (A), or $A\beta_{pE3-42}$ only (B), $*P$ < 0.001 for both. Flies were grown at 25 °C. Data are presented as means \pm SEM and were analysed by Student's *t* test. GMR-GAL4 was used to drive expression of $A\beta_{1-42}$ and $A\beta_{Q3-42}$ transgenic flies. (PDF 303 kb)

Abbreviations

AD: Alzheimer's disease; APP: amyloid precursor protein; A β : Amyloid beta; elavGS: elav GeneSwitch; ER: Endoplasmic reticulum; IDE: Insulin degrading enzyme; JNK/SAPK: c-Jun N-terminal kinase/stress-activated protein kinase; Nep2: Neprilysin2; pGlu: Pyroglutamic; QC: glutaminy cyclase; RU486, RU: mifepristone

Acknowledgements

We thank Dr D Crowther and Dr H Tricoire for their kind donation of UAS- $A\beta_{42}$ and elavGS fly stocks respectively. We thank Dr Kerr and Dr Woodling for help with blind scoring of eye data.

Funding

This work was supported by grants from the Max Planck Institute for the Biology of Ageing (MK, IS, LP), Alzheimer's Society (OS-A) and the Wellcome Trust (LP).

Availability of supporting data

Supporting data have been included in the publication as supplementary figures.

Authors' contributions

OS-A conceived experiments, performed experiments, analysed the data and wrote the manuscript. MK and IS performed experiments, and analyzed the data. LT generated UAS- $A\beta_{Q3-42}$ transgenic flies. LP contributed to supervision of the project and writing of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interest.

Consent for publication

All authors have given consent for publication.

Ethical approval and consent to participate

Not applicable.

Authors' information

Not applicable.

Author details

¹Institute of Healthy Ageing, and G.E.E., University College London, Darwin Building, Gower Street, London WC1E 6BT, UK. ²Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Straße 9B, 50931 Cologne, Germany. ³Center for Development of Advanced Medicine for Dementia (CAMD), National Center for Geriatrics and Gerontology (NCGG), Obu, Aichi, Japan.

Received: 7 September 2016 Accepted: 23 September 2016

Published online: 07 October 2016

References

- Serrano-Pozo A, Froesch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med*. 2011;1:a006189.
- Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256:184–5.
- Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide—the first step of a fatal cascade. *J Neurochem*. 2004;91:513–20.
- Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. *Biochim Biophys Acta*. 1812;2011:1359–70.
- Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Bux H, et al. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. *J Neurochem*. 2001;76:435–41.
- Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. *Science*. 2000;287:664–6.

7. Yarza R, Vela S, Solas M, Ramirez MJ. c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease. *Front Pharmacol*. 2015;6:321.
8. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. *Annu Rev Neurosci*. 2011;34:185–204.
9. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. *Annu Rev Pharmacol Toxicol*. 2003;43:545–84.
10. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, et al. Potent amyloidogenicity and pathogenicity of A β 43. *Nat Neurosci*. 2011;14:1023–32.
11. Burnouf S, Gorsky MK, Dols J, Grönke S, Partridge L. A β 43 is neurotoxic and primes aggregation of A β 40 in vivo. *Acta Neuropathol*. 2015;130:35–47.
12. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. *J Biol Chem*. 1992;267:17082–6.
13. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. *Neurosci Lett*. 1996;215:173–6.
14. Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid- β (A β): a hatchet man in Alzheimer disease. *J Biol Chem*. 2011;286:38825–32.
15. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth H-U. Glutaminy cyclases unfold glutamyl cyclase activity under mild acid conditions. *FEBS Lett*. 2004;563:191–6.
16. Cynis H, Schilling S, Bodnár M, Hoffmann T, Heiser U, Saido TC, et al. Inhibition of glutaminy cyclase alters pyroglutamate formation in mammalian cells. *Biochim Biophys Acta*. 2006;1764:1618–25.
17. Schilling S, Appl T, Hoffmann T, Cynis H, Schulz K, Jagla W, et al. Inhibition of glutaminy cyclase prevents pGlu-A β formation after intracortical/hippocampal microinjection in vivo/in situ. *J Neurochem*. 2008;106:1225–36.
18. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, et al. Glutaminy cyclase inhibition attenuates pyroglutamate A β and Alzheimer's disease-like pathology. *Nat Med*. 2008;14:1106–11.
19. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK. Heterogeneity of water-soluble amyloid β -peptide in Alzheimer's disease and Down's syndrome brains. *FEBS Lett*. 1997;409:411–6.
20. Perez-Garmendia R, Gevorkian G. Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer's Disease Immunotherapy. *Curr Neuropharmacol*. 2013;11:491–8.
21. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct β -amyloid peptide species, A β N3(pE), in senile plaques. *Neuron*. 1995;14:457–66.
22. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. *J Neurochem*. 2003;85:1581–91.
23. Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. *Am J Pathol*. 1996;149:1823–30.
24. He W, Barrow CJ. The A β 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater β -sheet forming and aggregation propensities in vitro than full-length A β . *Biochemistry*. 1999;38:10871–7.
25. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid- β . *Nature*. 2012;485:651–5.
26. Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, et al. Identification of Low Molecular Weight Pyroglutamate A β Oligomers in Alzheimer Disease. *J Biol Chem*. 2010;285:41517–24.
27. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth H-U, Bayer TA. Intraneuronal pyroglutamate-A β 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. *Acta Neuropathol*. 2009;118:487–96.
28. Alexandru A, Jagla W, Graubner S, Becker A, Bauscher C, Kohlmann S, et al. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A β is induced by pyroglutamate-A β formation. *J Neurosci*. 2011;31:12790–801.
29. Jawhar S, Wirths O, Schilling S, Graubner S, Demuth H-U, Bayer TA. Overexpression of glutaminy cyclase, the enzyme responsible for pyroglutamate A β formation, induces behavioral deficits, and glutaminy cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. *J Biol Chem*. 2011;286:4454–60.
30. Schilling S, Lindner C, Koch B, Wermann M, Rahfeld J-U, von Bohlen A, et al. Isolation and characterization of glutaminy cyclases from *Drosophila*: evidence for enzyme forms with different subcellular localization. *Biochemistry*. 2007;46:10921–30.
31. Sofola O, Kerr F, Rogers I, Killick R, Augustin H, Gandy C, et al. Inhibition of GSK-3 ameliorates A β pathology in an adult-onset *Drosophila* model of Alzheimer's disease. *PLoS Genet*. 2010;6:e1001087.
32. Crowther D, Page R, Chandraratna D, Lomas D. A *Drosophila* model of Alzheimer's disease. *Methods Enzymol*. 2006;412:234–55.
33. Iijima K, Liu H-P, Chiang A-S, Hearn SA, Konsolaki M, Zhong Y. Dissecting the pathological effects of human A β 40 and A β 42 in *Drosophila*: A potential model for Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2004;101:6623–8.
34. Osterwalder T, Yoon KS, White BH, Keshishian H. A conditional tissue-specific transgene expression system using inducible GAL4. *Proc Natl Acad Sci U S A*. 2001;98:12596–601.
35. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FAI, et al. Intraneuronal A β , non-amyloid aggregates and neurodegeneration in a *Drosophila* model of Alzheimer's disease. *Neuroscience*. 2005;132:123–35.
36. Omata Y, Lim Y-M, Akao Y, Tsuda L. Age-induced reduction of autophagy-related gene expression is associated with onset of Alzheimer's disease. *Am J Neurodegener Dis*. 2014;3:134–42.
37. Johannning K, Juliano MA, Juliano L, Lazure C, Lamango NS, Steiner DF, et al. Specificity of prohormone convertase 2 on proenkephalin and proenkephalin-related substrates. *J Biol Chem*. 1998;273:22672–80.
38. Rogers I, Kerr F, Martinez P, Hardy J, Lovestone S, Partridge L. Ageing increases vulnerability to A β 42 toxicity in *Drosophila*. *PLoS ONE*. 2012;7:e40569.
39. Jonson M, Pokrzywa M, Starkenberg A, Hammarstrom P, Thor S. Systematic A β Analysis in *Drosophila* Reveals High Toxicity for the 1-42, 3-42 and 11-42 Peptides, and Emphasizes N- and C-Terminal Residues. *PLoS ONE*. 2015;10:e0133272.
40. Tare M, Modi RM, Nainaparampil JJ, Poli OR, Bedi S, Fernandez-Funez P, et al. Activation of JNK signaling mediates amyloid- β -dependent cell death. *PLoS ONE*. 2011;6:e24361.
41. Hong YK, Lee S, Park SH, Lee JH, Han SY, Kim ST, et al. Inhibition of JNK/dFOXO pathway and caspases rescues neurological impairments in *Drosophila* Alzheimer's disease model. *Biochem Biophys Res Commun*. 2012;419:49–53.
42. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for studying Alzheimer's A β 42-induced toxicity in *Drosophila melanogaster*. *Mol Cell Neurosci*. 2004;26:365–75.
43. Marr RA, Guan H, Rockenstein E, Kindy M, Gage FH, Verma I, et al. Nephrilysin regulates amyloid Beta peptide levels. *J Mol Neurosci*. 2004;22:5–11.
44. Huang JY, Hafez DM, James BD, Bennett DA, Marr RA. Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease. *J Alzheimers Dis*. 2012;28:433–41.
45. Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, et al. Pyroglutamate A β pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. *J Neural Transm*. 2010;117:85–96.
46. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. *Neuron*. 2003;40:1087–93.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

